Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110406 | 0.97 | MAPT (0.40) | KMT2ATHRBPPARGHTTMAPT | |
| SCHEMBL816206 | 0.94 | THRB (0.40) | KMT2ATHRBAKR1C3PPARGHTT | |
| SCHEMBL20110402 | 0.92 | MAPT (0.37) | KMT2ATHRBPPARGHTTMAPT | |
| SCHEMBL12604129 | 0.92 | HTT (0.37) | KMT2ATHRBAKR1C3PPARGHTT | |
| SCHEMBL12893470 | 0.91 | THRB (0.41) | KMT2ATHRBAKR1C3PPARGHTT | |
| SCHEMBL25767943 | 0.90 | HTT (0.41) | KMT2ATHRBHTTMAPTTDP1 | |
| SCHEMBL24937951 | 0.89 | THRB (0.43) | KMT2ATHRBPPARGHTTMAPT | |
| SCHEMBL22430188 | 0.88 | THRB (0.45) | KMT2ATHRBFFAR1HTTMAPT | |
| SCHEMBL14000686 | 0.88 | THRB (0.45) | KMT2ATHRBFFAR1HTTMAPT | |
| SCHEMBL21791890 | 0.88 | THRB (0.49) | KMT2ATHRBPPARGHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119014-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL POLYMERIZED FILMS | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119014-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL POLYMERIZED FILMS | NAP1L1, CCNA1, NAP1L4 | KMT2A 2060/4885THRB 4871/4885FFAR1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.